Clinical Trials Update: Sept. 1, 2006
Bladder Disorders Restless Legs Breast Cancer
(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:
This trial will evaluate an investigational gel for overactive bladder. Volunteers 18 or older may be eligible with a history of the following symptoms: urgency (sudden urges to urinate), urge urinary incontinence (occasional leakage or wetting), and urinary frequency (the need to urinate more often than most people).
The research site is in Portland, Ore.
This study will evaluate an extended release formula for restless legs syndrome. The study will last approximately four months and will require 10 office visits. Candidates 18 or older with a body mass index (BMI) of less than 34 may qualify if they have no history of: other sleep disorders (such as sleep apnea or insomnia), uncontrolled diabetes, neurological disease, movement disorder (such as multiple sclerosis), or alcohol/drug abuse in the past 12 months.
The research site is in Salisbury, N.C.
This study will compare three different treatment schedules of ABI-007 (abraxane) in combination with bevacizumab in women with metastatic breast cancer. Volunteers older than 18 may be eligible if they have pathologically confirmed adenocarcinoma of the breast, Stage IV disease, and it's been at least four weeks since radiotherapy and major surgery. Participants also must have ECOG performance status 0-2 in order to qualify. Other criteria apply.
The research sites are located across the United States.
Copyright 2006 Thomson CenterWatch. All rights reserved.